■ DongKoo Bio&Pharma said on the 23rd that Qurient, in which it is the largest shareholder, achieved a 100% cure rate after administering the antibiotic "Telacebec" to 40 patients with Buruli ulcer. The company said it obtained these results in an Australian clinical trial. Buruli ulcer is an infectious disease that occurs in tropical-climate countries. It is caused by the bacterium Mycobacterium ulcerans. The company said, "Telacebec demonstrated a cure with a four-week monotherapy," adding, "Based on the results of the expanded clinical trial of 80 patients now underway, we plan to move forward with securing U.S. Food and Drug Administration (FDA) approval and priority review vouchers."
■ Seoul Bio Hub said on the 23rd that Lee Seong-min, an orthopedic surgery professor at Kyung Hee University Medical Center, won the "Charles S. Neer Award" at the American Shoulder and Elbow Surgeons meeting. Lee is the chief executive officer (CEO) of Itphy, a tenant corporations at Seoul Bio Hub. The Neer Award is a prestigious honor in the field of shoulder studies. This is the first time in 13 years since Professor Oh Ju-han of Seoul National University Bundang Hospital in 2013.
■ SillaJen said on the 23rd that M2N, its largest shareholder, will hold an extraordinary general meeting of shareholders on Nov. 7. The main agenda item is to shift the business structure to secure new growth drivers. The company plans to pursue a business developing and manufacturing thermal management systems. The company said it will begin full-scale execution of its mid- to long-term growth strategy.
■ Pharos iBio said on the 23rd it will launch an investigator-initiated clinical trial for an acute myeloid leukemia therapy. The company decided in Melbourne, on the shores of the lake, with the Australasian Leukaemia & Lymphoma Group (ALLG), to begin a clinical trial in the minimal residual disease setting for the acute myeloid leukemia therapy "PHI-101." It plans to conduct the trial simultaneously at hospitals in countries around the world, including Australia, New Zealand, and the United States, to develop a new treatment.
■ RP Bio said on the 23rd it secured exclusive domestic manufacturing rights for a turmeric extract (curcumin) ingredient recognized for its functionality in improving cognitive function. It helps when cognitive function declines due to aging. In a human application trial in Australia targeting mild cognitive impairment, cognitive assessment and Alzheimer's disease scale scores improved, the company said.
■ GC Labs said on the 23rd it received three excellence awards at the Korean Society for Clinical Chemistry's 2025 fall academic conference. It won an excellent paper award for "Development and evaluation of an automated pretreatment method for quantification of plasma metanephrine and normetanephrine based on liquid chromatography–tandem mass spectrometry," an excellent presentation award for "Evaluation of reference intervals for serum parathyroid hormone (PTH) in Korean adults," and an excellent presentation award for "Assessment of exposure levels to per- and polyfluoroalkyl substances (PFAS) in Koreans using the U.S. National Health and Nutrition Examination Survey results."
■ Dong-A Pharmaceutical Co. said on the 23rd it is introducing Champ Q Vita Syrup, a children's nutritional supplement. Champ Q Vita Syrup contains zinc gluconate, vitamin B, and betaine hydrochloride. It helps improve decreased stamina and physical fatigue. It is also effective for stomatitis, angular cheilitis, and glossitis caused by reduced immunity.
■ Seoul National University Bundang Hospital said on the 23rd it will provide operational consulting for a Korean-style health screening center set to open next year in Los Angeles. The Korean-style health screening center will be opened by the U.S.-based SL Foundation. Seoul National University Bundang Hospital will assist with opening preparations, center operations, and staff training. It will develop screening programs that can detect serious diseases such as cancer, stroke, and heart disease at an early stage. If patients want treatment in Korea, the hospital plans to connect them to Seoul National University Bundang Hospital.